Stocks-CRSP-CRISPR Therapeutics AG

CRSP CRISPR Therapeutics AG

62.78 -1.80 (-2.79%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest
Invest

FINANCIAL SUMMARY

For the quarter ended 31/3/2023, CRISPR Therapeutics AG's revenues increased by 1,666,566.67% and amounted to 100.00M. Net income increased by 52.01% to -53.07M. Net assets decreased by NaN to N/A and EPS increased from -1.41 to -0.67.
CRSP's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
27.99%
Net Profit Margin
-21,601.86%
Operating Margin
-560.23%
Return On Investment
-14.41%